Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

Documenti analoghi

• A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection
  di: Azar Shahraz, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors
  di: Heiko Babel, et al.
  Pubblicazione: (2026)
• QPRapp: A Web‐Based Platform for PK/PD Simulations and Early Feasibility Analysis
  di: Saroj Dhakal, et al.
  Pubblicazione: (2025)
• Evaluation of the PK / PD Changes on MASLD ‐Related Population—An Example From Simultaneous Acetaminophen Parent‐Metabolite PBPK / PD Modeling
  di: Shanshan Zhao, et al.
  Pubblicazione: (2025)
• The Regularized Horseshoe for Covariate Selection Improves Convenience and Predictive Performance in Population PK / PD Models
  di: Arya Pourzanjani, et al.
  Pubblicazione: (2026)